Comparison of Efficacy of Labetalol versus Alphamethyldopa in the Management of Preeclampsia
risk of adverse outcomes. Preeclampsia is a multi-system disorder of unknown etiology, unique to pregnancy characterized by
the occurrence of gestational hypertension along with proteinuria after the 20th week of pregnancy in a previously normotensive
and non-proteinuric patient.
Aim: The aim of the study was to study the efficacy of oral labetalol versus oral Alpha-methyldopa in the management of
Methods: Hundred patients included in this study were assigned to two groups randomly of 50 patients in each group. Group 1:
Tablet Alpha-methyldopa (Aldomet) 250 mg was given thrice daily, and Group 2: Tablet Labetalol 100 mg was given twice daily.
Blood pressure (BP) and proteinuria were recorded every 12th h.
Results: Significant fall in the diastolic BP after 48 h occurred only in the labetalol group (P = 0.007). In the Alpha-methyldopa
group, there was a significant need to increase the drug dose after 48 h (P = 0.043). There appears to be no significant difference
in induction rate between the two groups (P = 0.585). The mean birth weight was significantly higher (P = 0.00) in the labetalol
group (3.11 kg) compared to the alpha methyldopa group (2.67 kg). There was no significant difference in the Appearance,
Pulse, Grimace, Activity, and Respiration scores (P = 0.090) and rate of neonatal admissions (P = 0.240) in both groups.
Conclusion: Labetalol controls systolic and diastolic BP more rapidly and effectively than methyldopa. The safety profile and
adverse effects of Labetalol and Methyldopa are similar to each other.
2. Mammaro A, Carrara S, Cavaliere A, Ermito S, Dinatale A, Pappalardo EM,
et al. Hypertensive disorders of pregnancy. J Prenat Med 2009;3:1-5.
3. Côté AM, Brown MA, Lam E, von Dadelszen P, Firoz T, Liston RM, et al.
Diagnostic accuracy of urinary spot protein: Creatinine ratio for proteinuria
in hypertensive pregnant women: Systematic review. BMJ 2008;336:1003-6.
4. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia.
5. Uzan J, Carbonnel M, Piconne O, Asmar R, Ayoubi JM. Preeclampsia:
Pathophysiology, diagnosis, and management. Vasc Health Risk Manage
6. Kattah AG, Garovic VD. The management of hypertension in pregnancy.
Adv Chronic Kidney Dis 2013;20:229-39.
7. Pickles CJ, Broughton Pipkin F, Symonds EM. A randomised placebo
controlled trial of labetalol in the treatment of mild to moderate pregnancy
induced hypertension. BJOG Int J Obstet Gynaecol 1992;99:964-8.
8. El-Qarmalawi AM, Morsy AH, Al-Fadly A, Obeid A, Hashem M.
Labetalol VS. methyldopa in the treatment of pregnancy-induced
hypertension. Int J Gynaecol Obstet 1995;49:125-30.
9. Plouin PF, Breart G, Maillard F, Papiernik E, Relier JP. Comparison of
antihypertensive efficacy and perinatal safety of labetalol and methyldopa
in the treatment of hypertension in pregnancy: A randomized controlled
trial. Br J Obstet Gynaecol 1988;95:868-76.